2025 Q4 -tulosraportti
Vain PDF
118 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenWhat can one look forward to in the Q2 report on August 31?
- ·11 t sittenTalented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
- ·11 t sitten · MuokattuThis can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
·15 t sitten · MuokattuThere it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
118 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenWhat can one look forward to in the Q2 report on August 31?
- ·11 t sittenTalented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
- ·11 t sitten · MuokattuThis can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
- ·15 t sitten · MuokattuThere it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
118 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenWhat can one look forward to in the Q2 report on August 31?
- ·11 t sittenTalented people deserve a stage. Tekinvestor. "One more thing: no one else has managed what Circio is doing with its circVec. Just so that's clear. Wiklund has said that at some point an actor might emerge who solves what they do in a similar way, but that it will take many years before anyone is close. And by then, Circio will hopefully be clinically validated and absolutely market-leading within circRNA. It was also CTO Birkeballe and CEO Wiklund who gave the molecule the name circRNA back in 2012, when they were the first in the world to discover that circRNA has an important function in human cells. Birkeballe is literally "the founding father" of a field that many players are now investing in and where several billion-class transactions have recently been made. Everyone who studies circRNA, and everyone who develops therapeutic methods with circRNA, relies on Birkeballe's research. One can in many ways say that Circio IS circRNA."
- ·11 t sitten · MuokattuThis can surely be repeated so that any new ones are updated. Timeline autumn 2026 Circio. When can info/news come? Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations. Preclinical data in H2 2026 (Important) * In vivo CAR-T-data. * Efficacy data within wet AMD (eye treatment). * Heart disease model. * CNS proof-of-concept from the ongoing big pharma partner. This is considered by analysts as the most value-creating triggers towards a possible licensing agreement. Extraordinary General Meeting – August 25 * Election of Dinah Sah to the board. * Will strengthen the company's industrial profile. * October Publication of the ESGCT abstract with full data. October ESGCT oral presentation * Circio presents the circVec platform in front of a large international audience of pharmaceutical companies and potential partners. When? The most likely timeline is: * August 2026 * Updates from existing partners. Update Big Pharma collaboration…? New partnerships or research collaborations can come at any time. * September 2026 * The first preclinical data are expected: * In vivo CAR-T * Wet AMD * Heart disease model * CNS proof-of-concept from the big pharma collaboration Analysts point to these as the most important value drivers towards a first licensing agreement. The next 2–3 months could be very news-rich. The trigger the market is probably waiting for most is the first strong preclinical efficacy data, especially within in vivo CAR-T and the CNS program, since positive results can lay the foundation for a licensing or partnership agreement and an update on Big Pharma collaboration.
- ·15 t sitten · MuokattuThere it crashed, yes! Within one minute, the price really plunged. Perhaps someone put out a large block at the price the market is willing to give, and then it quickly goes the wrong way!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt